A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07512063
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-world setting.

Key Dates

First listed
Apr 6, 2026
Start date
Oct 8, 2024
Status verified
Mar 2026
Primary completion
Mar 17, 2025
Completion
Mar 17, 2025

Study Design

Enrollment
480 participants (actual)

Arms

  • Arm: CDK4/6i Cohort
    Adult HR+/HER2- mBC patients treated with 1L ribociclib, palbociclib, or abemaciclib.

Primary Outcome Measure

Number and Percentage of Patients Treated With 1L Ribociclib by Demographic Category [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
NovartisEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Novartis· East Hanover, NJ

Related Studies